Mahmoud Mahmoudian

Mahmoud Mahmoudian, Ph.D., FRSC, is a biopharmaceutical industry veteran who brings more than 30 years of global R&D, venture, and business development expertise driving growth strategies that identify and develop next-generation innovations into cures for major diseases that transform patients' lives. Most recently, Dr. Mahmoudian served as Senior Vice President and Head of Global Oncology External Innovation Hub at Sumitomo Dainippon Pharma Oncology (Sumitomo Oncology), where he led biotechnology investments, venture creation, company building, and expedited the discovery, incubation and regulatory approval of cell therapies, oncolytic viruses and other novel therapeutic technologies. Dr. Mahmoudian raised $70 million in capital to build academic and venture hubs. He also established oncology research alliances with Columbia University, the Wistar Institute, Harvard University, and the Dana-Farber Cancer Institute, and scouted venture capital investment opportunities that led to Sumitomo Oncology’s investment in the MPM Oncology Innovations Fund.

Dr. Mahmoudian previously served as Vice President, Head of Innovative Medicines at Ferring, Chief Innovation Officer and Chair of Executive Committee for Growth at Rohm & Haas (acquired by Dow) and Chief Biotechnology Officer at Eastman. At Merck and GlaxoSmithKline, he led global drug development teams with eight FDA approvals and product launches responsible for $15B in annual sales. Dr. Mahmoudian earned his Doctorate and Master of Science in Biotechnology from the Imperial College of Science, Technology and Medicine in London, UK. He is a Fellow of the Royal Society of Chemistry and an Executive in Residence at Columbia and Princeton universities.